Table 1.

Salemeterol treatment increased the turn-over rate of dopamine in the mouse striatum in MPTP Parkinson’s disease model

	DA (Mean ± SE)	DOPAC (Mean ± SE)	% (DOPAC/DA)	HVA (Mean ± SE)	% (HVA/DA)
Saline control	748.5 ± 76.7	123.0 ± 14.3	16.4	107.1 ± 4.26	14.3
MPTP	266.0 ± 22.18	81.33 ± 10.2	30.5	73.11 ± 5.66	27.4
Salmeterol (10 ug/kg/day)	668.6 ± 67.05	193.3 ± 28.0	28.8	101.9 ± 7.81	16.5
MPTP + Salmeterol (1ug/kg/day)	214.1± 16.89	148.2 ± 9.7	69.2	85.68 ± 2.68	39.7
MPTP + Salmeterol (10ug/kg/day)	205.6 ± 16.23	165.9 ± 8.8	80.5	97.18 ± 5.77	47.3

For 6 consecutive days, 8-wk-old C57BL/6 male mice received daily MPTP injections (15 mg/kg of MPTP·HCl (14.52 mg/kg as a base), s.c.). Salmeterol (1or 10 μg/kg/day) was given by continuous infusion (via an Alzet mini-pump) for 2 weeks starting at two days before the first MPTP injection. Mice used as controls received an equal volume of 0.9% saline. The mice were euthanized 21 days after the last MPTP/saline treatment with an i.p. injectionof 120 mg/kg pentobarbital and then perfused through the left ventricle with saline. Striatum region was dissected for the analysis of levels of DA and its metabolites, DOPAC and HVA. The trun-over rates were expressed by the ratio of DOPAC/DA and HVA/DA. The values of the DA, DOPAC and HVA are expressed as ng/100 mg of wet weight. Numbers of animal are 5–8 per group.